GSK obtains an exclusive right of first negotiation for a portion of technologies discovered.

GlaxoSmithKline (GSK) signed a five-year collaboration with the Immune Disease Institute in Boston (IDI) worth $25M to accelerate research in immunoinflammation.

IDI’s immunological expertise will be combined with GSK’s pharmaceutical capabilities. This partnership allows researchers at both institutions to develop joint grant proposals under what will be called the Alliance Research grant program.

Additionally, GSK receives an exclusive right of first negotiation for a substantial portion of the new technologies discovered and disclosed by IDI scientists during the term of the agreement. The research will be anchored through GSK’s Immuno-Inflammation Centre of Excellence in Drug Discovery.

Previous articleProteomika Licenses Auguron Technology to Advance Diagnostic Development in Autoimmune Diseases
Next articleMemory B Cells Linked to RA and Response to Rituximab